Antisense drug discovery and development

被引：2

作者：

Yamamoto, Tsuyoshi ^{[1
]}

Nakatani, Moeka ^{[1
]}

Narukawa, Keisuke ^{[1
]}

Obika, Satoshi ^{[1
]}

机构：

[1] Osaka Univ, Grad Sch Pharmaceut Sci, Suita, Osaka 5650871, Japan

来源：

FUTURE MEDICINAL CHEMISTRY | 2011年 / 3卷 / 03期

关键词：

LOCKED NUCLEIC-ACID; SOLID-PHASE SYNTHESIS; DUCHENNE MUSCULAR-DYSTROPHY; RESTRICTED NUCLEOSIDE ANALOGS; HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN APOLIPOPROTEIN B-100; RIBONUCLEIC GUANIDINE RNG; H-PHOSPHONOTHIOATE METHOD; MOTIF TRIPLEX FORMATION; SHOW IMPROVED POTENCY;

D O I：

10.4155/FMC.11.2

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Numerous chemically modified oligonucleotides have been developed so far and show their own unique chemical properties and pharmacodynamic/pharmacokinetic characteristics. Among all non-natural nucleotides, to the best of our knowledge, only five chemistries are currently being tested in clinical trials: phosphorothioate, 2'-O-methyl RNA, 2'-O-methoxyethyl RNA, 2',4'-bridged nucleic acid/locked nucleic acid and the phosphorodiamidate morpholino oligomer. Since phosphorothioate modification can improve the pharmacokinetics of oligonucleotides, this modification is currently used in combination with all other modifications except phosphorodiamidate morpholino oligomer. For the treatment of metabolic, cardiovascular, cancer and other systemic diseases, the phosphorothioate class of drugs is obviously helpful, while superior efficacies can be observed in phosphorodiamidate morpholino oligomer compared to other classes of oligonucleotides for the treatment of Duchenne muscular dystrophy. Which properties of antisense molecules are actually essential for clinical applications? In this article, we provide an overview of the medicinal chemistry of existing non-natural antisense molecules, as well as their clinical applications, to discuss which properties of antisense oligonuculeotides affect therapeutic potency.

引用

页码：339 / 365

页数：27

共 50 条

[41] An overview of drug discovery and development
Berdigaliyev, Nurken
Aljofan, Mohamad
[J]. FUTURE MEDICINAL CHEMISTRY, 2020, 12 (10) : 939 - 947
[42] Bioinformatics in drug discovery and development
Wishart, DS
[J]. DRUG METABOLISM REVIEWS, 2004, 36 : 13 - 13
[43] Drug Development: Portals of Discovery
Bates, Susan E.
Amiri-Kordestani, Laleh
Giaccone, Giuseppe
[J]. CLINICAL CANCER RESEARCH, 2012, 18 (01) : 23 - 32
[44] Drug discovery and Assay development
[J]. Nature Biotechnology, 2002, 20 (7) : 749 - 749
[45] Metabolomics in Drug Discovery and Development
Robertson, D. G.
Frevert, U.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (05) : 559 - 561
[46] Future drug discovery and development
Hurko, Orest
[J]. MOLECULAR GENETICS AND METABOLISM, 2010, 100 : S92 - S96
[47] THE REGULATION OF DISCOVERY AND DRUG DEVELOPMENT
OATES, JA
WOOD, AJJ
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (05): : 311 - 312
[48] Ophthalmic Drug Discovery and Development
Gukasyan, Hovhannes J.
Hailu, Shumet
Karami, Thomas K.
[J]. PHARMACEUTICAL RESEARCH, 2019, 36 (05)
[49] Outsourcing drug discovery & development
Glaser, V
[J]. GENETIC ENGINEERING NEWS, 2005, 25 (15): : 23 - +
[50] AIDS DRUG DISCOVERY AND DEVELOPMENT
MCGOWAN, J
HOTH, D
[J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1989, 2 (04): : 335 - 343

← 1 2 3 4 5 →